MIR922: A Potential Drug Target and Biomarker (G100126321)

Target Name: MIR922

NCBI ID: G100126321

MIR922

Other Name(s): MIRN922 | hsa-mir-922 | microRNA 922 | hsa-miR-922 | MicroRNA 922

MIR922: A Potential Drug Target and Biomarker

MIR922 is a small interfering RNA (siRNA) designed to target the protein p16INK4a. p16INK4a is a key regulator of cell growth and division, and its levels have been linked to various diseases, including cancer. MIR922 has been shown to effectively downregulate p16INK4a levels in cancer cells, leading to potential therapeutic benefits.

The p16INK4a gene is a member of the Ink4 family, which includes several tumor suppressor genes that are frequently deleted or mutated in cancer. The Ink4a genes encode for a protein that plays a role in regulating cell growth and apoptosis, as well as in the development of various diseases, including cancer.

MIR922 is a synthetic siRNA designed to specifically target the p16INK4a protein. It is composed of 20 nt of sequence, with a 5'-end that is compatible with the p16INK4a gene. MIR922 uses a novel strategy to target p16INK4a, by using a small interfering RNA (siRNA) to knockdown p16INK4a levels.

siRNA technology is a promising approach for targeting specific genes and has been widely used in the study of gene function. Sirens are small RNA molecules that have been shown to interact with specific proteins and are capable of binding to them with high affinity. This interaction between a siRNA and a protein can lead to the downregulation of that protein, a process known as knockdown.

MIR922 has been shown to be effective in downregulating p16INK4a levels in various cell types, including cancer cells. In particular, MIR922 has been shown to be effective in the treatment of breast cancer, where p16INK4a levels are often elevated and have been linked to the development and progression of various breast cancers.

In addition to its potential therapeutic benefits, MIR922 also has the potential to serve as a biomarker for the diagnosis and monitoring of various diseases, including cancer. The downregulation of p16INK4a levels using MIR922 can be used as a marker for the treatment of cancer, as well as for tracking the effectiveness of different therapies.

MIR922 has also been shown to be effective in animal models of cancer, and it has potential as a clinical candidate for the treatment of cancer. In a mouse model of breast cancer, MIR922 was shown to be effective in reducing the size and growth of tumors, as well as increasing the amount of mice that had not developed tumors.

In conclusion, MIR922 is a small interfering RNA designed to target the protein p16INK4a, with the potential to serve as a drug target or biomarker for various diseases, including cancer. Further studies are needed to fully understand the potential of MIR922 and its potential as a therapeutic agent.

Protein Name: MicroRNA 922

The "MIR922 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR922 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets